Institute for Medical Education and Research, Madelyn Trupkin Herzfeld, IMER, imer, imier, Miami, Florida, Nursing CE's, Nursing contact hours, nursing education, continuing education, medical research and education, Oncology, Postgraduate credit, oncology nurses, nurses, symposia, symposium, online educational credit, Breast Cancer, Cancer, cancer, breast cancer, colorectal cancer, Colorectal Cancer, Targeting EGFR, EGFR Inhibitors, egfr inhibitors, head and neck cancer, Anti-VEGF, VEGF Inhibitors, vegf inhibitors, lung cancer, head cancer, CINV, cinv, Chemotherapy Induced Nausea & Vomiting, chemotherapy, nausea, vomiting, mucositis, cancer pain, chronic pain  
Pathway to a Cure: New Treatment Strategies for Multiple Myeloma
Home > Breast Cancer  
 

Advances in Chemotherapy Options for Metastatic Breast Cancer: The Introduction of Epothilones

Continuing Education Regional Symposium for Oncology Nurses

Saturday, November 10, 2007
6:00 am – 8:00 am (CST)

The Fairmont Chicago
Crystal Room
Chicago, Illinois

Release Date: May 2008
Expiration Date: May 2009
Estimated Time to Complete Activity: 70 minutes (Adobe Flash Player and Adobe Acrobat Reader required)

I have read and understand the information presented on this page and agree to proceed with the educational activity.

Accreditation Information

Target Audience

This activity has been designed to meet the educational needs of oncologists caring for patients with metastatic breast cancer (MBC).

Purpose

To review current treatment options for patients with MBC and to discuss the emerging role of epothilones in the therapeutic spectrum.

Program Overview

More than 50,000 women will develop recurrent or MBC in 2007. Treatment for patients whose tumors are not hormone-sensitive or are refractory to hormone manipulation typically includes systemic chemotherapy with or without a biologic agent. Among the various treatment options, targeting of the microtubule has been shown to be an effective means of producing anticancer effects, as evidenced by the widespread incorporation of vinca alkaloids and taxanes into treatment regimens. However, these treatments are often associated with a narrow margin between benefit and toxicity, and resistance develops with continued use. The epothilones, with broad-spectrum antitumor effects, are a new addition to the antimicrotubule chemotherapy class. These agents have been under investigation in MBC in recent years. Epothilones have demonstrated antitumor activity in taxane-resistant cancer cells and they are now under investigation as single agents and in combination with other chemotherapies and biologic agents in patients who have failed taxane therapy. This program is intended to educate oncologists about current clinical research on epothilones, their mechanism of action, and how this class of agents fits in the treatment landscape for MBC.

Learning Objectives

Upon completion of this program, participants should be better able to:
  • Describe current standards of care for patients with MBC
  • Explain the mechanisms of action of drugs affecting the microtubule
  • Discuss recent clinical trial results of epothilone chemotherapies in MBC
  • Describe the side-effect profile of epothilone chemotherapies studied in patients with breast cancer
  • Cite the role of epothilone chemotherapies within the metastatic treatment setting

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM) and IMER do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM and IMER. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications , and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison to recommendations of other authorities.

Sponsored by:

IMER
 PIM
  Click on logo to visit site.

 

This activity is supported by an independent educational grant from Bristol-Myers Squibb Company.
 
Faculty

Sridhar Mani, MD
Assistant Professor of Medicine
Albert Einstein College of Medicine

Dr. Mani is associate professor of medicine at Albert Einstein College of Medicine of Yeshiva University in New York City. He received his doctor of medicine from Mount Sinai School of Medicine in New York City and completed postgraduate studies in hematology and oncology at Yale University in New Haven, Connecticut. His research interests include drug development and molecular and genetic pharmacology. Dr. Mani is the recipient of many awards, including the Damon Runyon Clinical Investigator Award and the Miriam Mandel Scholar Award. He has written or cowritten a multitude of articles and book chapters and is a scientific reviewer for several journals including Cancer, Journal of Clinical Oncology, and Clinical Cancer Research.

Privacy Policy

When you participate in a CME activity  provided by the Postgraduate Institute for Medicine (“PIM” or “we”), we ask you for your name, degree, affiliation, street address, telephone number, fax number, and e-mail address (the “Information”).  We use that Information in the following ways:

We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.

For each CME activity that you take, you must complete an evaluation questionnaire.  That questionnaire asks if you are willing to participate in a follow-up survey.  If you answer yes, we will use your name and contact information to send you the survey.

We may use the Information to invite you to participate in other CME activities that PIM or its affiliates may offer.

On occasion, the commercial supporter of a CME activity will ask us for a list of the people who participated in that activity, so that it may document the first level of outcomes-based evaluation in CME (i.e., who attended, which medical specialties/practices were represented, how this compares to the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend).  In that event, we will provide the supporter with your name, title and affiliation, but we will request in writing that the supporter not contact you directly for any purpose.

If our company is acquired or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.

Any changes to our privacy policy will be posted here immediately.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this educational activity:

Linda T. Vahdat, MD, has a financial interest/relationship or affiliation in the form of: Consultant, Bristol-Myers Squibb Company, Eisai Co., Ltd., Pfizer, Inc., Berlex Laboratories, and GPS Biotech; Contracted Research, Bristol-Myers Squibb Company, Eisai Co., Ltd., Pfizer, Inc., Berlex Laboratories, and GPS Biotech.

Sridhar Mani, MD, has reported no areas of conflict.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this educational activity:

Madelyn T. Herzfeld, RN, BSN, OCN®, has reported no areas of conflict.

Michael Bramwell, has reported no areas of conflict.

Davecia Ragoonath, MS, has reported no areas of conflict.

Jan Hixon, RN, BSN, MA, has reported no areas of conflict.

Linda Graham, RN, has reported no areas of conflict.

Trace Hutchison, PharmD, has reported no areas of conflict.

Accreditation Statements

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Institute for Medical Education & Research (IMER). PIM is accredited by the ACCME to provide continuing medical education for physicians.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Credit Designation

PIM designates this educational activity for a maximum of 1.1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating and receiving CME credit for this activity.

Participants must complete the posttest by recording the best answer to each question. Once you finished your test and completed the subsequent evaluation form, click submit test to send your responsed to us. Your test will be immediately reviewed and if you receive a passing grade of 70% or better, you will then be directed to print your certificate online.

Media

Web site

 

  
   

© Copyright 2003 – 2008 Institute for Medical Education & Research, Inc. All Rights Reserved.